Singapore: HSA Introduces Change Management Program (CMP) for SaMD, Including Machine-Learning Enabled SaMD

The Health Sciences Authority (HSA) of Singapore has issued a new guidance document,
“GN-37-R1 Change Management Program (CMP) for SaMD, including machine-learning enabled SaMD,” which became effective on 4th December 2024.

Key Highlights of GN-37-R1

Introduction of the Change Management Program (CMP)

  • The CMP provides a framework for “pre-specified changes” that SaMD manufacturers can implement without requiring a formal Change Notification submission.
  • “Pre-specified changes” must align with the SaMD’s original intended use and indication for use to qualify under CMP.

Assessment of Changes

  • Changes approved within a CMP must still be assessed in accordance with GN-37 to ensure compliance.
  • Any changes outside the scope of CMP-approved modifications must adhere to:
    • GN-21 Guidance on Change Notification for Registered Medical Devices
    • Regulatory Guidelines for Software Medical Devices – A Life Cycle Approach (specific to ML-SaMD).

Benefits of CMP for SaMD Manufacturers

The CMP program offers several advantages:

  • Greater Efficiency: Streamlines the implementation of software updates while maintaining compliance with regulatory requirements.
  • Regulatory Clarity: Provides clear pathways for managing changes, especially for machine-learning-enabled SaMDs.
  • Operational Flexibility: Reduces administrative burden by eliminating the need for Change Notifications for pre-approved changes.

Next Steps for SaMD Manufacturers

  • Review GN-37-R1 Guidance: Ensure a thorough understanding of CMP criteria and the scope of “pre-specified changes”.
  • Evaluate Current Change Processes: Align internal processes with the CMP framework to leverage its benefits.
  • Plan Compliance Measures: Identify changes that qualify for CMP and establish protocols for non-CMP changes per GN-21 or relevant guidelines.

Further Information

For additional details, consult the official guidance document: HSA: Medical Device Guidance.

For inquiries or assistance, contact us at sales@andamanmed.com or click the button below to contact us.

Sign up for our regulatory roundup delivered once a month to your inbox

Scroll to Top

Contact Us

Contact Form Demo

Don’t miss a single regulatory shift in Southeast Asia!

Subscribe to our Newsletter
Be the first to know about critical medical device regulation changes, market entry requirements, and industry shifts.

Andaman Medical - Mar Socials 2025 (11)